SURPLEMENTAL INFORMATION
SURPLEMENTAL INFORMATION
SP 12 2004 DISCLOSURE STATEMENT

_		
	Atty. Docket No.	Serial No.
	28967/35255B	10/661,740
	Applicant(s) Ferrell et al.	
	Filing Date September 12, 2003	Art Unit 1632 635

Examiner Initials	Document Number	Issue or Publication Date Name Name Name Rosen et al.			Subclass	Filing Date (If Appropriate)
JEA	2002/0120123		Rosen et al.			04-23-2002
Ī	2002/0146420	10-10-2002	Bennett et al.			10-17-2001
	2002/0151489	10-17-2002	Gravereaux et al.			10-02-2001
	2002/0182683	12-05-2002	Hu et al.			02-01-2002
	2003/0008357	01-09-2003	Hu et al.			08-24-2001
	2003/0166873	09-04-2003	Lee et al.			01-17-2003
	2003/0211988	11-13-2003	Epstein			01-09-2001
	2003/0232437	12-18-2003	Zhang et al.			06-17-2002
	5,932,540	08-03-1999	Hu et al.			
	5,935,820	08-10-1999	Hu et al.			
	6,107,046	08-22-2000	Alitalo et al.			
	6,221,839	04-24-2001	Alitalo et al.			
	6,245,530	06-12-2001	Alitalo et al.			
	6,331,302	12-18-2001	Bennett et al.			
	6,361,946	03-26-2002	Alitalo et al.			
	6,403,088	06-11-2002	Alitalo et al.			
	6,451,764	09-17-2002	Lee et al.			
	6,576,608	06-10-2003	Lee et al.			
	6,608,182	08-19-2003	Rosen et al.			
	6,645,933	11-11-2003	Alitalo et al.			
V	6,673,343	01-06-2004	Bennett et al.			

EXAMINER:	/Jon Eric Angell/	DATE CONSIDERED:	06/08/2006

SHEET	2	of	2
-------	---	----	---

Form PTQ-1449 (Modified)	Atty. Docket No.	Serial No:	
SUPPLEMENTAL INFORMATION SP 11 200 DISCLOSURE STATEMENT	28967/35255B	10/661,740	
	Applicant(s) Ferrell et al.		
	Filing Date	Art Unit	
	September 12, 2003	1632 1675	

Examiner	Document	Publication	Country	Translation
Initials	Number	Date	·	Yes No
JEA	WO 00/45835	08-10-2000	PCT	
JEA	WO 96/39515	12-12-1996	PCT	

EXAMINER: /Jon Eric Angell/ DATE CONSIDERED: 06/08/2006



Attorney Docket No.

28967/35255B

Applicant
Ferrell et al.

Filing Date
September 12, 2003

Serial No.

10/661,740

Group

Tosa:

10/661,740

INFORMATION DISCLOSURE STATEMENT

			U.S. PATE	NT DOCUMENTS			
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
JEA	A1	5,002,867	03/26/91	Macevicz, S.C.	435	6	
	A2	5,143,854	09/01/92	Pirrung, et al.	436	518	
	A3	5,202,231	04/13/93	Drmanac, et al.	435	6	
	A4	5,521,065	05/28/96	Whiteley, et al.	435	6	
	A5	5,631,237	05/20/97	Dzau, et al.	514	44	
	A6	5,776,755	07/07/98	Alitalo, et al.	435	194	
	A7	5,792,453	08/11/98	Hammond, et al.	424	93.21	
	A8	5,837,832,	11/17/98	Chee, M. et al.	536	22.1	
	A9	6,040,157	3/21/00	Hu, et al.	435	69.4	
	A10	2003/0028007	2/6/03	Hu, et al.	536	23.5	
	A11	6,130,071	10/10/00	Alitalo et al.	435	69.4	
$\overline{}$	A12	6,171,799	01/09/01	Skibbens et al.	435	7.1	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials			Publication Date	Country	Class	Subclass	Translation	
	1.						Yes	No
JEA	Bl	WO 98/33917	08-06-98	PCT			1	
	B2	WO 98/07832	02-26-98	PCT				
	B3	WO 97/05250	2-13-97	PCT				
	B4	WO 01/51075	7-19-01	PCT				
	B5	WO 99/46364	9-16-99	PCT				1
	B6	WO 02/29087	4-11-02	PCT			1	
	B7	WO 02/83704	10-24-02	PCT			1	
A	B8	WO 02/83849	10-24-02	PCT	1	 	<u> </u>	<u> </u>

JEA	C1	Achen et al., "Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4)," Proc. Natl. Acad. Sci., USA, 95: 548-553 (January, 1998).
JEA	C2	Akane et al., "Direct Dideoxy Sequencing of Genomic DNA by Ligation-Mediated PCR," Biotechniques 16: 238-241 (1994).
JEA	C3	Aprelikova et al., "FLT4, a Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," Cancer Res., 52: 746-748 (1992).

EXAMINER /Jon Eric Angell/	ATE CONSIDERED 06/08/2006
----------------------------	---------------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.	Serial No.	
28967/35255B	:	10/661,740
Applicant Ferrell et al.		
Filing Date	Group	
September 12, 2003	ĺ	1632 (√37

INFORMATION DISCLOSURE STATEMENT

JEA	C4	Barrowman, J.A., "Gastrointestinal Lymphatics," in Lymph Stasis: Pathophysiology, Diagnosis and Treatment, Chapter 9, CRC Press, Boca Raton, FL, pp. 211-231 (1991).
	C5	Boshart et al., "A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," Cell, 41:521-530 (June, 1985).
	C6	Boultwood et al., "Molecular Mapping of Uncharacteristically small 5q deletions in two patient with the 5q-syndrome: Delineation of the critical region on 5q and identification of a 5q-breakpoint," Genomic, 19(3):425-432 (1994).
	C7	Browman et al., "Comprehensive Human Genetic Maps: Individual and Sex-Specific Variation in Recombination," Am. J. Hum. Genetic., 63:861-869 (1998).
	C8	Campbell-Beggs et al., "Chyloabdomen in a neonatal foal," Veterinary Record, 137: 96-98 (July, 1995).
	C9	Castenholz, A., "Structure of Initial and Collecting Lymphatic Vessels," in Lymph Stasis: Pathophysiology, Diagnosis, and Treatment, Chapter 2, CRC Press: Boca Raton, FL, pp.15-42 (1991).
	C10	Dale, R.F., "The Inheritance of Primary Lymphoedema," J. Med. Genet., 22: 274-278 (1985).
	C11	Davis et al., "Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression," Hum. Gene Ther., 4:151-159 (1993).
	C12	Dignam et al., "Balbiani Ring 3 in Chironomus tentans Encodes a 185-kDa Secretory Protein Which is Synthesized Throughout the Fourth Larval Instar," Gene, 88:133-40 (1990).
	C13	Douglas et al., "Direct Sequencing of Double-Stranded PCR Products Incorporating a Chemiluminescent Stection Procedure," Biotechniques, 14:824-828 (1993).
	C14	Drmanac, S. et al., "Accurate sequencing by hybridization for DNA diagnostics and individual genomics," <i>Nature Biotechnology</i> , 16: 54-58 (January, 1998)
	C15	Dumont et al., "Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3," Science, 282: 946-949 (October, 1998).
	C16	Evans, A.L. et al., "Mapping of Primary Congenital Lymphedema to the 5q35.3 Region," Am. J. Hum. Genet., 64:547-555 (1999).
	C17	Ferrell et al., "Hereditary lymphedema: evidence for linkage and genetic heterogeneity," Hum. Mol. Genetics, 7(13):2073-2078 (December, 1998).
	C18	Fischer et al., "DNA Fragments Differing by Single Base-Pair Substitutions are Separated in Denaturing Gradient Gels: Correspondence with Melting Theory," Proc. Natl. Acad. Sci., USA, 80: 1579-1583 (March, 1983).
	C19	Fournier et al., "Mutation in tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor," Oncogene, 11(5):921-931 (1995).
	C20	Fournier et al., "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling," Oncogene, 18(2):507-514 (January, 1999).
	C21	Fox, J.C. et al., "Angiogenic Gene Therapy," Circulation, 94:3065-3066 (1996).
	C22	Galland et al., "Chromosomal Localization of FLT4, a Novel Receptor-Type Tyrosine Kinase Gene," Genomics, 13: 475-478 (1992).
	C23	Galland et al., "The FLT4 Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," Oncogene, 8: 1233-1240 (1993).
	C24	Genbank Accession No. AF014827, Rattus norvegicus vascular endothelial growth factor D (VEGF-D) mRNA, complete cds.
$\overline{\mathbf{V}}$	C25	Genbank Accession No. AJ000185, Homo Sapiens mRNA for vascular endothelial growth factor-D.

EXAMINER /Jon Eric Angell/ DATE CONSIDERED 06/08/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.

28967/35255B

Applicant
Ferrell et al.

Filing Date
September 12, 2003

Serial No.

10/661,740

Forup

INFORMATION DISCLOSURE STATEMENT

		MENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
JEA	C26	Genbank Accession No. CCY15837, Coturnix coturnix mRNA for vascular endothelial growth factor C.		
	C27	Genbank Accession No. D89628, Mus musculus mRNA for vascular endothelial growth factor D, complete cds.		
	C28	Genbank Accession No. L07296, Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds.		
	C29	Genbank Accession No. U73620 (Locus MMU73620) Mus musculus VEGF-C mRNA, complete cds.		
	C30	Genbank Accession No. P35917, Vascular Endothelial Growth Factor Receptor 3 Precursor (VEGFR-3) (Tyrosine-Protein Kinase Receptor FLT4).		
	C31	Genbank Accession No. S66407, FLT4 = receptor tyrosine kinase isoform FLT4 long {3' region, alternatively spliced} [human, mRNA Partial, 216 nt].		
	C32	Genbank Accession No. X68203, H. sapiens mRNA for FLT4, class III receptor tyrosine kinase		
	C33	Genetic variants and strains of the laboratory mouse, 2nd ed., New York: Oxford University Press, p. 70 (1989).		
	C34	Gnatenko et al., "Characterization of Recombinant Adeno-Associated Virus-2 as a Vehicle for Gene Delivery and Expression into Vascular Cells," J. Investig. Med., 45: 87-98 (1997).		
	C35	Greenlee et al., "Developmental Disorders of the Lymphatic System," Lymphology, 26:156-168 (1993).		
	C36	Holmes et al., "Hereditary Late-Onset Lymphedema," Pediatrics 61:575-579 (1978).		
	C37	Isner et al., "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," Circulation, 91: 2687-2692 (1995).		
	C38	Isner et al., "Arterial Gene Therapy for Restenosis," Human Gene Therapy, 7: 989-1011 (May, 1996).		
	C39	Jabs et al., "A Mutation in the Homeodomain of the Human MSX2 Gene in a Family Affected with Autosomal Dominant Craniosynostosis," Cell, 75:443-450 (November, 1993).		
	C40	Jeltsch et al., "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," Science, 276:1423-1425 (May, 1997).		
	C41	Joukov et al., "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," EMBO J., 15:290-298 (1996).		
	C42	Joukov et al., "Proteolytic Processing Regulates Receptor Specificity and Activity of VEGR-C, EMBO J., 16(13): 3898-3911 (1997).		
	C43	Joukov et al., "A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeabilit Activities," J. Biol. Chem., 273(12): 6599-6602 (March, 1998).		
	C44	Jussila et al., "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Recetor-3," Cancer Res., 58: 1599-604 (April, 1998).		
	C45	Kaipainen, A., et al., "Expression of the fms-like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," Proc. Natl. Acad. Sci., USA, 92: 3566-3570 (April, 1995).		
	C46	Kieleczawa et al., "DNA Sequencing by Primer Walking with Strings of Contiguous Hexamers," Science, 258:1787-1791 (December, 1992).		
$\overline{\Psi}$	C47	Kim et al., "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1," J. Virol., 72(1): 811-816 (January, 1998).		

EXAMINER	/Jon Eric Angell/	DATE CONSIDERED 06/08/2006			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in					
conformance and not considered. Include copy of this form with next communication to applicant.					



Attorney Docket No. Serial No. 28967/35255B 10/661,740 Applicant Ferrell et al. Filing Date 1632 1635

September 12, 2003

INFORMATION DISCLOSURE STATEMENT

JEA	C48 Kingsman, A. & Johnson, E., "A New Generation of Gene Therapy Vectors," Scripp. 43-46 (October 1998).	
	C49	Kinmonth, J.B., in Kinmonth, J.B. (ed), <i>The Lymphatics: Diseases, Lymphography and Surgery</i> Edward Arnold Publishers: London, England (1972), pp. 82-86
	C50	Korhonen et al., "Endothelial-Specific Gene Expression Directed by the tie Gene Promoter In Vivo," Blood, 86(5): 1828-1835 (1995).
	C51	Kukk et al., "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development," <i>Development</i> , 122: 3829-3837 (1996).
	C52	Lehner et al., "Comparative Sequence Analysis of Human Cytomegalovirus Strains," J. Clin. Microbiol., 29:2494-2502 (November, 1991).
	C53	Levinson, K.L., "Linkage Analysis of Hereditary Lymphedema to Chromosome 5: Preliminary Analysis for a Genome Scan," Submitted to the Graduate Facility of the Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science, University of Pittsburgh, pp. ii-vii and 1-54 (1996).
	C54	Lewis et al., "Lymphedema praecox," J. Ped., 104:641-648 (May, 1984).
	C55	Lyon et al., "Research News," Mouse News Lett. 71: 26 (1984).
	C56	Maxam et al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages," Meth. Enzymol., 65: 499-560 (1977).
	C57	Miller et al., "A Simple Salting Out Procedure for Extracting DNA from Human Nucleated Cells," Nucleic Acids Res., 16: 1215 (1998).
	C58	Milroy, W.F., "An Undescribed Variety of Hereditary Edema," N.Y. Medical J., 56:505-508 (1892).
	C59	Mirzabekov, A.D., "DNA Sequencing by Hybridization - a Megasequencing Method and a Diagnostic Tool?" TIBTECH, 12: 27-32 (January, 1994).
	C60	Mohammadi et al., "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism," Cell, 86:577-587 (August, 1996).
	C61	Lyon et al., in: Mouse News Lett. 74: 96 (1986).
	C62	Myers et al., "Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA: DNA Duplexes," Science, 230: 1242-1246 (1985).
	C63	O'Connell, J.R. et al., "PedCheck: A Program for Identifying Marker Typing Incompatibilities in Linkage Analysis," D.E., Am. J. Hum. Genet., 61:A288 (1997) (ABSTRACT).
	C64	O'Connell, J.R. et al., "The VITESSE Algorithm for Rapid Exact Multilocus Linkage Analysis Via Genotype Set-Recoding and Fuzzy Inheritance," <i>Nature Genet.</i> , 11:402-408 (December, 1995).
	C65	Offori et al., "Angiosarcoma in Congenital Hereditary Lumphoedema (Milroy's Disease) - Diagnostic Beacons and a Review of the Literature," Clin. Exp. Dermatol., 18:174-177 (1993).
	C66	Oh et al., "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," Dev. Biol., 188:96-109 (1997).
	C67	Ohkuma, M., "Dermal Lymph and Lymphatics," in Lymph Stasis: Pathophysiology, Diagnosis and Treatment, Chapter 7, CRC Press, Boca Raton, FL, pp. 157-189 (1991).
	C68	Olszewski, W.L., "Chemistry of Lymph," in Lymph Stasis: Pathophysiology, Diagnosis, and Treatment, Chapter 10, CRC Press, Boca Raton, FL, pp. 235-258 (1991).
1/	C69	Orita et al., "Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms," Proc Natl. Acad. Sci., USA, 86: 2766-2770 (1989).

EXAMINER /Jon Eric Angell	/ DATE CONSIDERED	06/08/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.

28967/35255B

Applicant
Ferrell et al.

Filing Date
September 12, 2003

Serial No.

10/661,740

Group

INFORMATION DISCLOSURE STATEMENT


JEA	C70	Ott, J., "Computer-simulation Methods in Human Linkage Analysis," <i>Proc. Nat. Acad. Sci., USA</i> , 86:4175-4178 (June, 1989).
	C71	Pajusola et al., "FLT4 Receptor Tyrosine Kinase Contains Seven Immuoglobulin-Like Loops and Is Expressed in Multiple Human Tissues and Cell Lines," Cancer Res., 52:5738-5743 (October, 1992).
	C72	Pajusola et al., "Two Human FLT4 Receptor Tyrosine Kinase Isoforms with Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," Oncogene 8: 2931-2937 (1993).
	C73	Pajusola et al., "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related to Two VEGF Receptors," Oncogene, 9: 3545-3555 (1994).
	C74	Partanen et al., "Opposite phehotypes of hypomorphic and Y766 phosphorylation site mutation reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos," Genes & Development, 12: 2332-2344 (1998)
	C75	Pastinen et al., "Minisequencing: A Specific Tool for DNA Analysis and Diagnostics on Oligonucleotide Arrays," Genome Res., 7: 606-614 (1997).
	C76	Patterson et al., "Hereditary Lymphedema," Comparative Pathology Bulletin, 3: 2 (May, 1971)
	C77	Paulsson et al., "The Balbiani Ring 3 Gene in Chironomous tentans has a Diverged Repetitive Structure Split by Many Introns," J. Mol. Biol., 211:331-49 (1990).
	C78	Pease et al., "Light-generated Oligonucleotide Arrays for Rapid DNA Sequence Analysis," Proc. Natl. Acad. Sci., USA, 91:5022-5026 (May, 1994).
	C79	Quantin et al., "Adenovirus as an Expression Vector in Muscle Cells in Vivo," Proc. Natl. Aca Sci., USA, 89:2581-2584 (April, 1992).
	C80	Ramsay, G., "DNA Chips: State-of -the-Art," Nature Biotechnology, 16: 40-48 (January, 1998)
	C81	Riesner et al., "Temperature-gradient Gel Electrophoresis of Nucleic Acids: Analysis of Conformational Transitions, Sequence Variations, and Protein-Nucleic acid Interactions," Electrophoresis, 10: 377-389 (1989).
	C82	Roberts et al., "Potassium Permanganate and Tetraethylammonium Chloride are a Safe and Effective Substitute for Osmium Tetroxide in Solid-Phase Fluorescent Chemical Cleavage of Mismatch," Nucl. Acids Res., 25: 3377-3378 (1997).
	C83	Rosenfeld et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," Cell, 68: 143-155 (January, 1992).
	C84	Rowley et al.,"Ultrarapid Mutation Detection by Multiplex Solid-Phase Chemical Cleavage," Genomics, 30: 574-582 (1995).
	C85	Sambrook et al., Molecular Cloning: A Laboratory Manual (Second ed., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989) §§ 9.47-9.51.
	C86	Sanger et al., "DNA Sequencing With Chain-Terminating Inihibitors," Proc. Natl. Acad. Sci. (USA), 74:5463-5467 (December, 1977).
	C87	Schafer et al., "DNA Variation and the Future of Human Genetics," Nature Biotechnology, 16 33-39 (1998).
	C88	Drmanac, R. et al., "DNA sequence determination by hybridization: a strategy for efficient large-scale sequencing," [published erratum appears in Science 1994 Feb 4; 163(5147):596] Science (UNITED STATES), 260(5114):1649-52 (June, 1993).
	C89	Shumaker et al., "Mutation Detection by Solid Phase Primer Externsion," Human Mutation, 7: 346-354 (1996).
17	C90	Stratford-Perricadet et al., "Widespread Long-term Gene Transfer to Mouse Skeletal Muscles

EXAMINER /Jon Eric Angell/

DATE CONSIDERED

06/08/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Attorney Docket No.

28967/35255B

Applicant

Ferrell et al.

Filing Date

September 12, 2003

Serial No.

10/661,740

Applicant

Filing Date

September 12, 2003

INFORMATION DISCLOSURE STATEMENT

JEA	C91	Thompson et al., "The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis," Dev. Biol., 197:248-269 (1998).		
	C92	Tsurumi, Y. et al., "Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion," Circulation, 34:3281-3290 (1996).		
	C93	Tsurumi, Y. et al., "Treatment of Acute Limb Ischemia by Intramucular Injection of Vascular Endothelial Growth Factor Gene," Circulation, 96(Suppl. II):II-382-II-388 (1997).		
	C94	Uhley, H. and Leeds, S., "Pulmonary Lymph and Lymphatics," in Lymph Stasis: Pathophysiology, Diagnosis and Treatment, Chapter 8, CRC Press, Boca Raton, FL, pp. 191-209 (1991).		
	C95	Van Der Geer et al., "Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," Ann. Rev. Cell. Biol., 10:251-337 (1994).		
	C96	van der Putte, "Congenital Hereditary Lymphedema in the Pig," Lympho, 11: 1-9 (1978)		
	C97	Weeks et al., "SLINK: A General Simulation Program for Linkage Analysis," Am. J. Hum. Genet., 47: A204 (1990) (ABSTRACT).		
	C98	Wheeler et al., "Familial Lymphedema Praecox: Meige's Disease," Plastic Reconstructive Surg., 67:362-364 (1981).		
	C99	White et al., "Detecting Single Base Substitutions as Heteroduplex Polymorphisms," Genomical 12: 301-306 (1992).		
	C100	Witte et al., "Phentypic and genotypic hetherogeneity in familial Milroy lymphedema," Lymphology, 31(4):145-155 (1998).		
	C101	Yin et al., "Genomic Structure of the Human KDR/flk-1 Gene," Mammalian Genome, 9: 408-410 (1998).		
	C102	Kaipainen et al., "The Related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cell," J. Exp. Med., 178:2077-2088 (1993).		
	C103	Lymboussaki et al., "Expression of the vascular endothelial growth factor C receptor VEGFR-in lymphatic endothelium of the skin and in vascular tumors." Am. J. Pathol., 153:395-403 (1998).		
	C104	Partanen et al., "Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors." Cancer, 86:2406-12 (1999).		
	C105	Ruohola et al., "Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells," Mol. Cell. Endocrinol., 149:29-40 (1999).		
	C106	Taipale et al., "Vascular endothelial growth factor receptor-3", Curr. Top. Microbiol. Immunol 237: 85-96 (1999).		
	C107	Valtola et al., "VEGFR-3 and its ligand VEGF-C are associated with angoigenesis in breast cancer," Amer. J. Pathol., 154:3801-90 (1999).		
	C108	Kimak et al., "Linkage and mutation in the vascular endothelial growth factor-C receptor (FLT4) gene in hereditary lymphedema." American J. Human Genetics, 63(supplement):A34 (1998) Abstract 180		
	C109	Lawrence et al., "Vascular endothelial growth factor-C:Genomic organization, sequence and variation." American J. Human Genetics, 63(supplement): A185, (October 1998) Abstract 105.		
	C110	Ahern, H., "Biochemical, Reagent Kits Offer Scientists Good Return on Investment," www.thescientist.library.upenn.edu/yr1995/july/tools-950724.html		
\mathbf{I}	C111	Gene Characterization Kits, 1998 Stratagene Catalogue, pp 39-40.		
V	C112	Ding et al., "A Single Amino Acid Determines the Immunostimulatory Activity of Interleukin		

EXAMINER	/.Ton	Eric	Angell	1
SAMMINER	/.Ton	Fric	Angell	

DATE CONSIDERED 06/08/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.